Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Trial ID or NCT#

NCT02282930

Status

not recruiting iconNOT RECRUITING

Purpose

This study is designed to answer whether patients with progressive IgA nephropathy, who receive Acthar (ACTH) gel injection at a dose of 80 units subcutaneously twice weekly for 6 months is effective in inducing improvement in proteinuria and renal function.

Official Title

An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Contact us to find out if this trial is right for you.

Contact

Kshama R Mehta, Ph.D
650-736-1822

View on ClinicalTrials.gov